Metagenomi Therapeutics, Inc.(MGX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,952 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MGX Stock Analysis & AI Quality Score
Data updated 2026-09-10AI stock analysis and institutional research for Metagenomi Therapeutics, Inc. (MGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGX at 5.7/100 on a 32-signal composite quality model, placing it at rank #2,952 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.1) and free cash flow (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Metagenomi Therapeutics, Inc. reports net income of $-27.5M, free cash flow of $-19.6M. Top institutional holders of MGX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, Catalio Capital Management, based on the most recent SEC filings. MGX trades on the Nasdaq exchange and files with the SEC under CIK 1785279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Metagenomi Therapeutics, Inc. directly from SEC EDGAR. Metagenomi Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 15 since 2025, currently 5.7 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-27.5M
Free Cash Flow
Q2 2026
$-19.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-51.8% YoYNet Income
-12.6% YoYOperating Income
-8.0% YoYEPS (Diluted)
+0.0% YoYTotal Assets
-31.9% YoYOp. Cash Flow
+18.5% YoYFree Cash Flow
+20.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $25.2M -51.8% | $52.3M +16.8% | $44.8M | — |
| Net Income | $-87.9M -12.6% | $-78.1M -14.4% | $-68.3M | — |
| Operating Income | $-96.0M -8.0% | $-88.9M -13.3% | $-78.5M | — |
| EPS (Diluted) | $-2.36 +0.0% | $-2.36 +79.4% | $-11.48 | — |
| Total Assets | $221.1M -31.9% | $324.6M -11.0% | $364.8M | — |
| Operating Cash Flow | $-88.9M +18.5% | $-109.1M -19.3% | $-91.4M | — |
| Free Cash Flow | $-89.5M +20.3% | $-112.2M -10.8% | $-101.2M | — |
Get alerted when MGX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Metagenomi Therapeutics, Inc. including:
Top Institutional Holders of MGX
VANGUARD CAPITAL MANAGEMENT LLC
$1.3M1,077,700 shRENAISSANCE TECHNOLOGIES LLC
$883.5K742,400 shCatalio Capital Management, LP
$629.5K528,993 shPeapod Lane Capital LLC
$624.8K525,024 shTWO SIGMA INVESTMENTS, LP
$611.3K513,701 shBRIDGEWAY CAPITAL MANAGEMENT, LLC
$476.4K400,300 shWELLS FARGO & COMPANY/MN
$451.6K379,508 shGEODE CAPITAL MANAGEMENT, LLC
$343.7K288,665 shPURA VIDA INVESTMENTS, LLC
$314.6K264,391 shBlackRock, Inc.
$306.6K257,631 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | 1,077,700 |
| RENAISSANCE TECHNOLOGIES LLC | $883.5K | 742,400 |
| Catalio Capital Management, LP | $629.5K | 528,993 |
| Peapod Lane Capital LLC | $624.8K | 525,024 |
| TWO SIGMA INVESTMENTS, LP | $611.3K | 513,701 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $476.4K | 400,300 |
| WELLS FARGO & COMPANY/MN | $451.6K | 379,508 |
| GEODE CAPITAL MANAGEMENT, LLC | $343.7K | 288,665 |
| PURA VIDA INVESTMENTS, LLC | $314.6K | 264,391 |
| BlackRock, Inc. | $306.6K | 257,631 |
Companies Similar to MGX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Outset Medical, Inc.
DocGo Inc.
MAXCYTE, INC.
Centessa Pharmaceuticals plc
Dianthus Therapeutics, Inc. /DE/
ORASURE TECHNOLOGIES INC
Keros Therapeutics, Inc.
Scilex Holding Co
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MGX on your watchlist
Track score changes the day Metagenomi Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MGX a good stock to buy?
13F Pro's AI-powered analysis of Metagenomi Therapeutics, Inc. (MGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MGX are available on the MGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MGX is classified as a small company.
Which hedge funds own MGX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Metagenomi Therapeutics, Inc.'s investment landscape.